New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
16:11 EDTACTActavis files ANDA for Dalfampridine tablets
Actavis confirmed that it has filed an Abbreviated New Drug Application, or ANDA, with the FDA seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra, which is indicated as a treatment to improve walking in patients with multiple sclerosis.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use